SiBone (NASDAQ:SIBN – Get Free Report) Director Timothy Davis, Jr. sold 3,500 shares of SiBone stock in a transaction that occurred on Friday, May 29th. The shares were sold at an average price of $14.14, for a total transaction of $49,490.00. Following the sale, the director directly owned 65,722 shares in the company, valued at $929,309.08. This trade represents a 5.06% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink.
SiBone Trading Down 1.6%
Shares of SiBone stock opened at $13.87 on Tuesday. SiBone has a 1 year low of $11.48 and a 1 year high of $21.89. The company has a current ratio of 9.99, a quick ratio of 8.34 and a debt-to-equity ratio of 0.20. The firm has a market capitalization of $615.12 million, a PE ratio of -35.56 and a beta of 0.67. The firm’s 50 day moving average is $13.55 and its 200 day moving average is $16.03.
SiBone (NASDAQ:SIBN – Get Free Report) last posted its earnings results on Monday, May 11th. The company reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.17) by $0.07. SiBone had a negative net margin of 8.10% and a negative return on equity of 9.56%. The firm had revenue of $52.59 million for the quarter, compared to analyst estimates of $51.16 million. Equities research analysts forecast that SiBone will post -0.44 earnings per share for the current fiscal year.
Wall Street Analysts Forecast Growth
Read Our Latest Research Report on SIBN
Institutional Trading of SiBone
Hedge funds and other institutional investors have recently modified their holdings of the business. ANTIPODES PARTNERS Ltd bought a new stake in shares of SiBone in the fourth quarter valued at approximately $29,000. Royal Bank of Canada raised its stake in SiBone by 98.5% in the fourth quarter. Royal Bank of Canada now owns 1,483 shares of the company’s stock valued at $29,000 after purchasing an additional 736 shares in the last quarter. Caitong International Asset Management Co. Ltd raised its stake in SiBone by 64,700.0% in the fourth quarter. Caitong International Asset Management Co. Ltd now owns 1,944 shares of the company’s stock valued at $38,000 after purchasing an additional 1,941 shares in the last quarter. Kemnay Advisory Services Inc. purchased a new stake in SiBone in the fourth quarter valued at approximately $53,000. Finally, State of Wyoming purchased a new position in shares of SiBone during the second quarter worth approximately $55,000. Institutional investors own 98.11% of the company’s stock.
SiBone Company Profile
Si-BONE, Inc is a commercial‐stage medical device company focused on the design, development and commercialization of implant systems to treat degenerative conditions of the sacroiliac (SI) joint. Its flagship product, the iFuse Implant System, consists of triangular titanium implants that are inserted via a minimally invasive surgical procedure to stabilize the SI joint and alleviate chronic lower back and buttock pain.
FDA‐cleared in 2012, the iFuse portfolio has expanded to include the iFuse-3D and iFuse-3Di devices, which feature a porous, 3D-printed surface to promote bone ongrowth and biological fixation.
Featured Stories
- Five stocks we like better than SiBone
- Why These Three Big Buybacks Are Sending Very Different Signals to Investors
- Drone Stocks Soar As Pentagon Considers Funding, Including a Trump-Linked Name
- Braze Blazes Ahead on Q1 2027 Earnings Beat, Raised Guidance
- Are the 3 Newest Members of the $1 Trillion Market Cap Club the Latest Sign of an AI Bubble?
Receive News & Ratings for SiBone Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SiBone and related companies with MarketBeat.com's FREE daily email newsletter.
